RESUMO
Introducción: Los biomarcadores son claves en el diagnóstico y pronóstico del lupus eritematoso sistémico en el cual las manifestaciones clínicas son extremadamente complejas y heterogéneas. Objetivo: Determinar el valor clínico de los inmunocomplejos circulantes en pacientes con lupus eritematosos sistémico. Métodos: Se determinaron los niveles séricos de inmunocomplejos fijadores del C1q y de los anticuerpos anti-ácido desoxirribonucleico de doble cadena (anti-ADNdc), anti-nucleosoma (anti-Nuc) y anti-proteínas ribosomales (anti-RibP) por el ensayo inmuno-adsorbente ligado a enzima (ELISA) en 93 pacientes con diagnóstico de lupus eritematosos sistémico. Se utilizaron exámenes no paramétricos para probar la asociación entre los inmunocomplejos y los auto-anticuerpos. La frecuencia de nefritis lupica en los grupos de pacientes positivos y negativos de inmunocomplejos circulantes se comparó mediante Chi cuadrado. Resultados: Los inmunocomplejos se encontraron en 24 (25,8 por ciento) pacientes con lupus eritematosos sistémico. Los pacientes que presentaron los títulos más altos de inmunocomplejos fueron los positivos a los tres auto-anticuerpos usados (p=0,044). Se encontró correlación directa entre los niveles de anti-RibP y los inmunocomplejos (Rho=0,303, p=0,003) y entre los anti-ADNdc y anti-Nuc (Rho=0,449, p=0,001). La nefritis lúpica se presentó en 58,3 por ciento de pacientes con inmunocomplejos, y 31,9 por ciento pacientes negativos de inmunocomplejos (p=0,213). Conclusiones: Los inmunocomplejos circulantes caracterizaron una fracción menor de pacientes con lupus eritematosos sistémico. La presencia de estos no se asoció a los anticuerpos anti-ADNdc ni a la nefritis lupica(AU)
Introduction: Biomarkers are essential in the diagnosis and prognosis of systemic erythematous lupus in which clinical manifestations are extremely complex and heterogeneous. Objective: To determine the clinical value of circulating immunocomplexes in patients with systemic erythematous lupus. Methods: Serum levels of C1q-binding immunocomplexes and anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nucleosome (anti-Nuc) and anti-ribosomal proteins (anti-RibP) were determined by enzyme-linked immunosorbent assay (ELISA) in 93 patients diagnosed with systemic lupus erythematosus. Nonparametric tests were used to test the association between immunocomplexes and auto-antibodies. The frequency of lupus nephritis in the circulating immunocomplex positive and negative patient groups was compared using Chi square. Results: Immunocomplexes were found in 24 (25.8 percent) patients with systemic lupus erythematosus. The patients with the highest immunocomplex titers were positive for the three autoantibodies used (p = 0.044). A direct correlation was found between the levels of anti-RibP and immunocomplexes (Rho = 0.303, p = 0.003) and between anti-dsDNA and anti-Nuc (Rho = 0.449, p = 0.001). Lupus nephritis occurred in 58.3 percent of immunocomplex patients, and 31.9 percent immunocomplex negative patients (p = 0.213). Conclusions: Circulating immunocomplexes characterized a smaller fraction of patients with systemic lupus erythematosus. Their presence was not associated with anti-dsDNA antibodies or lupus nephritis(AU)
Assuntos
Humanos , Masculino , Feminino , Ensaio de Imunoadsorção Enzimática/métodos , Biomarcadores Tumorais/análise , Lúpus Eritematoso Sistêmico/diagnóstico , Estudos Transversais , ISCOMs/análiseRESUMO
The purpose of this study was to investigate the effect of a new infectious bursal disease (IBD) immune complex vaccine on immune system response in both specific pathogen-free (SPF) and commercial birds. Evaluation of response to the vaccination in the two experiments was done by histopathological examination and serology. The results of this study have shown that immune complex vaccine with the V877 strain is quite safe in White Leghorn SPF birds in which there has been no participation of maternal antibodies. In commercial birds was also observed that the immune complex vaccine with the V877 strain acted synergistically with different levels of passive antibodies and the vaccine virus began to replicate as passive immunity decreased to provide the animal active immunological response.
O objetivo desse estudo foi investigar o efeito de uma nova vacina de imunocomplexo contra a doença de Gumboro sobre o sistema imune de aves SPF e comerciais. A avaliação da resposta à vacinação foi realizada por meio de exame histopatológico e sorologia. Os resultados desse estudo demonstraram que a vacina de imunocomplexo com cepa V877 contra Gumboro é muito segura mesmo em aves SPF da linhagem White Leghorn nas quais não existia a participação de imunidade materna. Em aves comerciais também foi demonstrado que a vacina de imunocomplexo com a cepa V877 atuou sinergicamente com diferentes níveis de anticorpos passivos maternais, iniciando a replicação do vírus vacinal a partir do momento que a imunidade passiva diminui, para promover uma resposta imunológica ativa.
Assuntos
Animais , Aves/imunologia , ISCOMs/análise , ISCOMs/efeitos adversos , Vírus da Doença Infecciosa da Bursa/imunologia , Medicamentos de Referência , Sorologia , VacinasRESUMO
The purpose of this study was to investigate the effect of a new infectious bursal disease (IBD) immune complex vaccine on immune system response in both specific pathogen-free (SPF) and commercial birds. Evaluation of response to the vaccination in the two experiments was done by histopathological examination and serology. The results of this study have shown that immune complex vaccine with the V877 strain is quite safe in White Leghorn SPF birds in which there has been no participation of maternal antibodies. In commercial birds was also observed that the immune complex vaccine with the V877 strain acted synergistically with different levels of passive antibodies and the vaccine virus began to replicate as passive immunity decreased to provide the animal active immunological response.(AU)
O objetivo desse estudo foi investigar o efeito de uma nova vacina de imunocomplexo contra a doença de Gumboro sobre o sistema imune de aves SPF e comerciais. A avaliação da resposta à vacinação foi realizada por meio de exame histopatológico e sorologia. Os resultados desse estudo demonstraram que a vacina de imunocomplexo com cepa V877 contra Gumboro é muito segura mesmo em aves SPF da linhagem White Leghorn nas quais não existia a participação de imunidade materna. Em aves comerciais também foi demonstrado que a vacina de imunocomplexo com a cepa V877 atuou sinergicamente com diferentes níveis de anticorpos passivos maternais, iniciando a replicação do vírus vacinal a partir do momento que a imunidade passiva diminui, para promover uma resposta imunológica ativa.(AU)